

Sweiss, Rami	van den Wijngaard, Rene	Watari, Jiro
Tack, Jan	van Geenen, Erwin	Wedemeyer, Heiner
Takagi, Tomohisa	van Oijen, Martijn	Weusten, Bas
Takatsu, Yasuo	Vandenplas, Yvan	Wheat, Chelle
Tang, S	Vanheel, Hanne	Whitcomb, David
Thiele, Maja	Vankemseke, Catherine	Whitehead, William
Tilg, Herbert	Vanuytsel, Tim	Wilcox, Charles
Tillmann, Hans	Vavricka, Stephan	Williams, John
Tomasula, RC	Vergani, Diego	Wouters, Mira
Toniutto, Pierluigi	Vieth, Michael	Wu, Justin CY
Törnblom, Hans	Villanacci, Vincenzo	Youngster, Ilan
Travis, Simon	Villanueva, Augusto	Zagari, Rocco Maurizio
Trebicka, Jonel	Voigtländer, Torsten	Zerbib, Frank
Ulahannan, Susanna	Vuppalanchi, Raj	Zingone, Fabiana
van Assche, Gert	Watanabe, Toshio	Zorger, Niels

---

## Erratum

United European Gastroenterology Journal  
2017, Vol. 5(2) 304  
© Author(s) 2016  
Reprints and permissions:  
[sagepub.co.uk/journalsPermissions.nav](http://sagepub.co.uk/journalsPermissions.nav)  
DOI: 10.1177/2050640616641615  
[journals.sagepub.com/home/ueg](http://journals.sagepub.com/home/ueg)



Robin Spiller, Fanny Pélerin, Amélie Cayzele Decherf, Corinne Maudet, Béatrice Housez, Murielle Cazaubiel and Peter Jüsten. Randomized double blind placebo-controlled trial of *Saccharomyces cerevisiae* CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation. *United European Gastroenterology Journal* 2016; 4: 353–362. doi: 10.1177/2050640615602571.

On page 357, in the section “Results on total population”, the abdominal pain/discomfort scores observed in both active and placebo groups have been inverted. This should read as:

“Considering abdominal pain/discomfort score, significant decrease was observed from the beginning to the end of supplementation, in both active and placebo groups (respectively, **−0.61** and **−0.43**,  $p < 0.0001$  in both groups).”